Stay updated with breaking news from Nuclear Export. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Free Report) has been assigned an average recommendation of “Moderate Buy” from the seven analysts that are presently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price objective among […]
Karyopharm Therapeutics (NASDAQ:KPTI – Get Rating) and Alimera Sciences (NASDAQ:ALIM – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends and profitability. Valuation and Earnings This table compares Karyopharm Therapeutics and […]
Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) has been assigned a consensus rating of “Moderate Buy” from the eight brokerages that are currently covering the company, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12 month target […]
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...
NEWTON, Mass., June 1, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. , a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an... | June 1, 2023